COVID-19

CPhI post-pandemic executive pharma survey: COVID-19 driving manufacturing and CDMOs driving growth

  • by

Ahead of CPhI Discover (17th-28th May, 2021) – global pharma’s largest ever virtual gathering – the CPhI executive post-pandemic pharma survey[i] predicts that pandemic supply chain issues have further cemented a push for repatriated manufacturing globally. The findings suggest that over the next five years, governments and companies will gradually… Read More »CPhI post-pandemic executive pharma survey: COVID-19 driving manufacturing and CDMOs driving growth

Russian Vaccine Behavior

  • by

In the last post, I mentioned the Twitter response to the Brazilian rejection of the Gamaleya vaccine. I believe that the official blue-check-marked “Sputnik V” Twitter account is run by the Russian Direct Investment Fund, the sovereign-wealth part of the Russian state that is in… Read More »Russian Vaccine Behavior

‘We’re Coming for You’: For Public Health Officials, a Year of Threats and Menace

  • by

[Editor’s note: This article contains strong language that readers might find offensive or disturbing.] SANTA CRUZ COUNTY, Calif. — Dr. Gail Newel looks back on the past year and struggles to articulate exactly when the public bellows of frustration around her covid-related health orders morphed… Read More »‘We’re Coming for You’: For Public Health Officials, a Year of Threats and Menace

A Look at Novavax

  • by

Lots of work going on today, so let me just send the readership to this excellent article about Novavax, by Jason Mast at Endpoints. That vaccine has moved into even more prominence lately with the recent adenovirus vaccine events, and it seems clear that it… Read More »A Look at Novavax

MedCity Spotlight Video: How Penn Center for Innovation is combating Covid-19 [Sponsored]

  • by

As part of MedCity’s 2021 INVEST conference, Cesar de la Fuente, presidential assistant professor at the University of Pennsylvania, explains the value of the rapid low-cost diagnostic test he has developed to detect SARS-CoV-2 and how the platform technology can be deployed to detect other… Read More »MedCity Spotlight Video: How Penn Center for Innovation is combating Covid-19 [Sponsored]

From Rotten Teeth to Advanced Cancer, Patients Feel the Effects of Treatment Delays

  • by

With medical visits picking up again among patients vaccinated against covid-19, health providers are starting to see the consequences of a year of pandemic-delayed preventive and emergency care as they find more advanced cancer and rotting and damaged teeth, among other ailments. This story also… Read More »From Rotten Teeth to Advanced Cancer, Patients Feel the Effects of Treatment Delays

Providers, payers are ready to listen, root out racism and regain the trust of minorities. Here’s how.

  • by

Racism has always existed in healthcare, but the Covid-19 pandemic laid bare how entrenched the problem still is. In response, providers and payers have vowed to fight for health equity by examining the racism within their organizations, listening to minority communities and mounting strategies that… Read More »Providers, payers are ready to listen, root out racism and regain the trust of minorities. Here’s how.

Lilly and Incyte Report Results of Baricitinib in P-III COV-BARRIER Study for Hospitalized Patients with COVID-19

  • by

Shots: The P-III COV-BARRIER study involves assessing Baricitinib (4mg, qd) + SoC (which included 79% receiving corticosteroids and 19% receiving remdesivir, with some receiving both) vs PBO + SoC in 1525 patients in a ratio (1:1) hospitalized with COVID-19 The trial did not meet 1EPs… Read More »Lilly and Incyte Report Results of Baricitinib in P-III COV-BARRIER Study for Hospitalized Patients with COVID-19

Journalists Unpack Patchwork Vaccine Rollout, Rapid Covid Tests and More

  • by

California Healthline correspondent Rachel Bluth unpacked California’s newly expanded vaccine eligibility rules and the state’s vaccine appointment website on KALW’s “Your Call” on Thursday. Click here to hear Bluth on KALW California Healthline correspondent Angela Hart discussed California cities’ experiment with city-managed homeless camps on… Read More »Journalists Unpack Patchwork Vaccine Rollout, Rapid Covid Tests and More

Merck Keeps Plowing On

  • by

I last wrote about the small-molecule antiviral malnupiravir here, and we finally have more information from Merck and Ridgeback about its effects in clinical trials. An interim analysis of the Phase II data from trials in both outpatients and in hospitalized coronavirus patients has been… Read More »Merck Keeps Plowing On

Cleveland Clinic researchers measure pandemic’s effect on Medicare population

  • by

Research conducted by the Cleveland Clinic and Massachusetts-based startup Health Data Analytics Institute (HDAI) measured the difference in mortality during the pandemic  between people covered by Medicare in long-term care facilities and in the community. While a Covid-19 diagnosis increased deaths in both settings, there… Read More »Cleveland Clinic researchers measure pandemic’s effect on Medicare population

A Year Into Pandemic, Federal Officials Design New Mask Guidelines to Better Protect More Workers

  • by

Federal officials announced new measures to help get fresh, new N95 masks to health care workers and expand their use in other industries after scientists argued that the highly protective masks are essential to keep workers safe from covid-19. Use Our Content It can be… Read More »A Year Into Pandemic, Federal Officials Design New Mask Guidelines to Better Protect More Workers

Redfield Joins Big Ass Fans, Which Promotes Controversial Covid-Killing Technology

  • by

Dr. Robert Redfield, former director of the Centers for Disease Control and Prevention, has joined Big Ass Fans, lending his scientific credibility to a company division that says its ion-generating technology kills the coronavirus. The company charges $9,450 for a fan with technology that academic… Read More »Redfield Joins Big Ass Fans, Which Promotes Controversial Covid-Killing Technology

ICYMI: New CBO Report highlights biopharmaceutical leadership in the development of new treatments and cures

  • by

America’s biopharmaceutical companies are at the heart of a research and development (R&D) ecosystem that develops more innovative medicines than any other country in the world. The ongoing development of new, life-saving and life-improving medicines, including those for COVID-19, would not be possible without the robust investment,… Read More »ICYMI: New CBO Report highlights biopharmaceutical leadership in the development of new treatments and cures

Vaccine Efficacy Questions

  • by

Next up on the vaccine news front are some concerns about efficacy. In a very surprising statement, Gao Fu (the head of the Chinese Center for Disease Control and Prevention) said at a conference in Chengdu over the weekend that that the protection figures of… Read More »Vaccine Efficacy Questions

AZ/Oxford Calculations

  • by

We have a lot of vaccine news to catch up on! First up is the latest on the possible clotting side effects seen with Oxford/AstraZeneca. This is looking more and more likely to be a rare-but-real effect, and I’m not happy that it’s holding up.… Read More »AZ/Oxford Calculations

AstraZeneca’s Farxiga (dapagliflozin) Fails to Meet its Primary Endpoint in P-III DARE-19 Trial for COVID 19

  • by

Shots: The P-III DARE-19 trial involves assessing the efficacy and safety of Farxiga vs PBO in addition to SoC therapy in 1,250 hospitalized patients with COVID-19 who are at high risk of developing serious complications The trial fails to meet its 1EP of prevention measures… Read More »AstraZeneca’s Farxiga (dapagliflozin) Fails to Meet its Primary Endpoint in P-III DARE-19 Trial for COVID 19

Roche Report Results of Ab Cocktail (Casirivimab + Imdevimab) in P-III REGN-COV 2069 Trial for Symptomatic COVID 19 Infection

  • by

Shots: The P-III REGN-COV 2069 trial involves assessing the efficacy and safety of Ab cocktail (casirivimab (1200 mg, SC) + imdevimab (1200 mg, SC) vs PBO in 1,505 people to prevent symptomatic infection in household contacts of individuals infected with COVID-19 The trial met its… Read More »Roche Report Results of Ab Cocktail (Casirivimab + Imdevimab) in P-III REGN-COV 2069 Trial for Symptomatic COVID 19 Infection

‘Go Ahead and Vote Me Out’: What Other Places Can Learn From Santa Rosa’s Tent City

  • by

SANTA ROSA, Calif. — They knew the neighborhood would revolt. It was early May, and officials in this Northern California city known for its farm-to-table dining culture and pumped-up housing prices were frantically debating how to keep covid-19 from infiltrating the homeless camps proliferating in… Read More »‘Go Ahead and Vote Me Out’: What Other Places Can Learn From Santa Rosa’s Tent City

How Doctors and Hospitals Can Help Defeat COVID-19 Vaccine Resistance and Misinformation

  • by

There’s a recent rise in national optimism that says—maybe—we have turned the corner on the pandemic lockdown. Admittedly, it’s been a tough year for nearly everyone, but miraculous vaccines and declining death rates have stirred newfound optimism. COVID-19 PUBLIC EDUCATION CAMPAIGN by the U.S. Department… Read More »How Doctors and Hospitals Can Help Defeat COVID-19 Vaccine Resistance and Misinformation

Getting Vaccinated

  • by

So as I mentioned on Twitter yesterday, I’ve now had my first coronavirus vaccine dose (Pfizer/BioNTech). Since I’ve been writing about the mRNA vaccines for months here and cheering on the vaccine efforts in general, I can tell you that I’m very, very happy to… Read More »Getting Vaccinated

Journalists Dive Deep Into Roots of Vaccine Distrust in Prisons and Covid’s Toll on Public Health

  • by

Reporter Eric Berger discussed vaccine hesitancy among inmates at a Missouri correctional center with Newsy on Thursday. Click here to watch Berger on Newsy Read Berger’s “Inmates’ Distrust of Prison Health Care Fuels Distrust of Covid Vaccines” KHN Editor-in-Chief Elisabeth Rosenthal discussed how the U.S.… Read More »Journalists Dive Deep Into Roots of Vaccine Distrust in Prisons and Covid’s Toll on Public Health

Excess deaths due to COVID-19

  • by

Using data from the National Center for Health Statistics (NCHS) and US Census Bureau, Woolf et al. (2021) find: Between March 1, 2020, and January 2, 2021, the US experienced 2 801 439 deaths, 22.9% more than expected, representing 522 368 excess deaths…The excess death rate was higher… Read More »Excess deaths due to COVID-19

Backed by Millions in Public and Private Cash, Rapid Covid Tests Are Coming to Stores Near You

  • by

Scientists and lawmakers agree that over-the-counter covid tests could allow desk workers to settle back into their cubicles and make it easier to reopen schools and travel. This story also ran on Fortune. It can be republished for free. But even as entrepreneurs race their… Read More »Backed by Millions in Public and Private Cash, Rapid Covid Tests Are Coming to Stores Near You

In California, Blue Shield’s Vaccination Takeover Fixes What Wasn’t Broken

  • by

In California’s Mendocino County, public health officials and community clinics say they have hit their vaccination stride. This story also ran on The Mendocino Beacon. It can be republished for free. Despite the county’s remoteness and its largely rural population spread among wooded mountains, rugged… Read More »In California, Blue Shield’s Vaccination Takeover Fixes What Wasn’t Broken

Dramática baja de enfermedades por virus comunes, ¿significa máscaras para siempre?

  • by

Las máscaras y el distanciamiento físico están demostrando tener importantes beneficios extra, evitando que las personas contraigan todo tipo de enfermedades, no solo covid-19. Pero no está claro si los protocolos valdrán la pena a largo plazo. Maestros de la Academia New Hope en Franklin,… Read More »Dramática baja de enfermedades por virus comunes, ¿significa máscaras para siempre?

We Are the Ever Given

  • by

By KIM BELLARD The Ever Given is free!  Admit it: you’ve been following the story about the huge container ship stuck in the Suez Canal.  It’s about the size of the Empire State building laid flat, and somehow ended up blocking one of the busiest… Read More »We Are the Ever Given

Eli Lilly along with VIR and GSK Report Results of Bamlanivimab + VIR-7831 in P-II BLAZE-4 Study for Low-Risk Adults with COVID

  • by

Shots: The P-II BLAZE-4 study involves assessing bamlanivimab as monothx. and bamlanivimab (700mg) + VIR-7831 (500mg) vs PBO in 1000 participants with symptomatic low-risk COVID-19 in the outpatient setting across the US and Puerto Rico Results: The dual regimen met its 1EPs i.e. 70% relative… Read More »Eli Lilly along with VIR and GSK Report Results of Bamlanivimab + VIR-7831 in P-II BLAZE-4 Study for Low-Risk Adults with COVID

Qiagen’s NeuMoDx Multiplex Test Receives the US FDA’s EUA and Expands its COVID-19 Portfolio

  • by

Shots: The US FDA has granted EUA for Qiagen’s NeuMoDx Flu A-B/RSV/SARS-CoV-2 Vantage Assay that will help in identifying and differentiate individuals suspected of respiratory viral infection consistent with COVID-19 Qiagen launched the multiplex test in the EU in Nov’2020 and will now begin commercialization… Read More »Qiagen’s NeuMoDx Multiplex Test Receives the US FDA’s EUA and Expands its COVID-19 Portfolio

It’s Not Just QAnon. Democrats and Independents Also Want to Recall California’s Governor.

  • by

SACRAMENTO — California Gov. Gavin Newsom is framing the burgeoning effort to remove him from office as a fringe Republican movement backed by right-wing extremists, Trump supporters and QAnon conspiracy theorists. Use Our Content It can be republished for free. But Newsom isn’t telling the… Read More »It’s Not Just QAnon. Democrats and Independents Also Want to Recall California’s Governor.

AstraZeneca updates Covid-19 vaccine data, now showing 76% efficacy

  • by

AstraZeneca’s latest efficacy data for its Covid-19 vaccine are down slightly from the 79% it previously reported. The most recent data will form the basis of an application for emergency use authorization, which the company still expects to file with the FDA in coming weeks.

Stop Blaming Tuskegee, Critics Say. It’s Not an ‘Excuse’ for Current Medical Racism.

  • by

For months, journalists, politicians and health officials — including New York Gov. Andrew Cuomo and Dr. Anthony Fauci — have invoked the infamous Tuskegee syphilis study to explain why Black Americans are more hesitant than white Americans to get the coronavirus vaccine. This story is… Read More »Stop Blaming Tuskegee, Critics Say. It’s Not an ‘Excuse’ for Current Medical Racism.

AstraZeneca Reports Results of AZD1222 in Primary Analysis of P-III Trial for the Prevention of COVID-19

  • by

Shots: The P-III D8110C00001 study involves assessing AZD1222 vs PBO in 32,449 participants in a ratio (2:1) aged ≥18yrs. across 88 trial centers in the US, Peru and Chile to prevent COVID-19. his primary efficacy analysis included the accrual of 190 symptomatic cases of COVID-19… Read More »AstraZeneca Reports Results of AZD1222 in Primary Analysis of P-III Trial for the Prevention of COVID-19

AstraZeneca’s Covid-19 vaccine data may have ‘outdated information,’ NIH cautions

  • by

Federal health authorities say safety observers are concerned AstraZeneca did not release complete information about the efficacy of its Covid-18 vaccine. The company responded by saying its data were from a pre-specified analysis and it will provide the most up to date efficacy data within… Read More »AstraZeneca’s Covid-19 vaccine data may have ‘outdated information,’ NIH cautions

ViewPoints Interview: SiO2’s Lawrence Ganti Shares Insight on the Efforts to Scale Up the Manufacturing of Vials for COVID-19 Vaccines

  • by

In an interview with PharmaShots, Lawrence Ganti, President & Chief Business Officer at SiO2 Materials Science shared his views on the efforts to scale up the manufacturing of vials to combat COVID-19. Additionally, he also shared the benefits of using SiO2’s smart vials and shed… Read More »ViewPoints Interview: SiO2’s Lawrence Ganti Shares Insight on the Efforts to Scale Up the Manufacturing of Vials for COVID-19 Vaccines

Regeneron Reports Results of REGEN-COV Antibody Cocktail in P-III Trial to Prevent COVID-19

  • by

Shots: The P-III trial involves assessing REGEN-COV (casirivimab & imdevimab, 1200/2400mg, IV) vs PBO in non-hospitalized patients with COVID-19 The trial met its 1EPs i.e. showed a reduction in the risk of hospitalization and death with both doses by 70% /71% respectively and met its… Read More »Regeneron Reports Results of REGEN-COV Antibody Cocktail in P-III Trial to Prevent COVID-19

‘Press 1 for English’: Vaccination Sign-Ups Prove Daunting for Speakers of Other Languages

  • by

In late February, a week after Virginia launched a centralized website and call center for covid-19 vaccine preregistration, Zowee Aquino alerted the state to a glitch that could prove fatal for non-English speakers trying to secure a shot. This story also ran on U.S. News… Read More »‘Press 1 for English’: Vaccination Sign-Ups Prove Daunting for Speakers of Other Languages

Covid-19 long-hauler clinics offer a ‘medical home’ for patients on uncharted journey

  • by

There is a growing demand for centralized care for Covid-19 long-haulers — that is, patients who had Covid-19 and recovered but continue to experience symptoms. Health systems are setting up clinics specifically for this patient population, which comes with its own set of opportunities and… Read More »Covid-19 long-hauler clinics offer a ‘medical home’ for patients on uncharted journey

Landmark Covid Relief Law Pumps More Than $100 Billion Into Public Health

  • by

Acknowledging that chronic underfunding of public health contributed significantly to the nation’s fragmented response to the coronavirus pandemic, Democrats included more than $100 billion in the recently enacted relief package to address urgent needs and enhance future efforts. Use Our Content It can be republished… Read More »Landmark Covid Relief Law Pumps More Than $100 Billion Into Public Health

How Covid Has Changed Our Movement, as Revealed by Your Cellphone

  • by

<![CDATA[ window.addEventListener(‘message’, function(event) { if (typeof event.data[‘datawrapper-height’] !== ‘undefined’) { var iframes = document.querySelectorAll(‘iframe’); for (var chartId in event.data[‘datawrapper-height’]) { for (var i=0; iFor all of our grousing about covid fatigue, a few novel trends are clear one year into the pandemic. Use Our Content… Read More »How Covid Has Changed Our Movement, as Revealed by Your Cellphone

Novartis and Molecular Partners Report Inclusion of Ensovibep (MP0420) in NIH-Sponsored ACTIV-3 Trial for the Treatment of COVID 19

  • by

Shots: The P-III ACTIV-3 trial plan to evaluate the safety & efficacy of Ensovibep (MP0420) vs PBO in 300 patients hospitalized with mild to moderate COVID-19. The first patient dosing is anticipated in Q2’21 If the ensovibep treatment has a positive benefit/risk profile, the trial… Read More »Novartis and Molecular Partners Report Inclusion of Ensovibep (MP0420) in NIH-Sponsored ACTIV-3 Trial for the Treatment of COVID 19

Avance Clinical Client Atossa Therapeutics Announces Final Results from Phase 1 Clinical Study Showing Safety and Tolerability of AT-301 Nasal Spray Being Developed for COVID-19

  • by

The leading Australian CRO for biotechs and Frost & Sullivan Asia-Pacific CRO Market Leadership Award winner Avance Clinical congratulated Atossa Therapeutics on the announcement of their Phase 1 final results for the AT-301 nasal spray being developed for COVID-19. Atossa Therapeutics, Inc. (Nasdaq: ATOS) is… Read More »Avance Clinical Client Atossa Therapeutics Announces Final Results from Phase 1 Clinical Study Showing Safety and Tolerability of AT-301 Nasal Spray Being Developed for COVID-19

Roche’s Actemra/RoActemra (tocilizumab) + Veklury Fail to Meet its Primary Endpoints in P-III REMDACTA Study for Patients with Severe COVID-19 Pneumonia

  • by

Shots: The P-III REMDACTA study involves assessing Actemra/RoActemra (tocilizumab) + Veklury (remdesivir) vs PBO + Veklury in hospitalized patients with severe COVID-19 pneumonia receiving SOC The study did not meet its 1EPs i.e. improvement in time to hospital discharge up to day28 and failed to… Read More »Roche’s Actemra/RoActemra (tocilizumab) + Veklury Fail to Meet its Primary Endpoints in P-III REMDACTA Study for Patients with Severe COVID-19 Pneumonia

Empatica’s Aura System Receives European CE Mark for Detecting Early Symptoms of COVID-19 Using Wearables

  • by

Shots: Empatica received its CE mark for Aura system as a class lla medical device, along with its remote health monitoring platform (Care) meet safety and performance requirements in the EU Aura system detects and alerts to respiratory infections including COVID-19, before the visible appearance… Read More »Empatica’s Aura System Receives European CE Mark for Detecting Early Symptoms of COVID-19 Using Wearables

Empatica’s Aura System Receives European CE Mark for Detecting Early Symptoms of COVID-19 Using Wearables

  • by

Shots: Empatica received its CE mark for Aura system as a class lla medical device, along with its remote health monitoring platform (Care) meet safety and performance requirements in the EU Aura system detects and alerts to respiratory infections including COVID-19, before the visible appearance… Read More »Empatica’s Aura System Receives European CE Mark for Detecting Early Symptoms of COVID-19 Using Wearables

Elli Lilly Reports Results of Bamlanivimab (LY-CoV555) and Etesevimab (LY-CoV016) in P-III BLAZE-1 Study for the Prevention of COVID-19

  • by

Shots: The P-III BLAZE-1 study involves assessing Bamlanivimab (700 mg) + Etesevimab (1400 mg) vs PBO in 769 COVID-19 patients aged ≥12yrs. who are at high risk for progressing to severe COVID-19 and/or hospitalization The results demonstrated an 87% reduction in hospitalizations and death with… Read More »Elli Lilly Reports Results of Bamlanivimab (LY-CoV555) and Etesevimab (LY-CoV016) in P-III BLAZE-1 Study for the Prevention of COVID-19

UK data hub to apply AI to health records for COVID-19 and respiratory research

  • by

Health Data Research UK’s respiratory hub BREATHE is set to use artificial intelligence (AI) to unlock real-world insights from electronic health records (EHRs) as part of a new partnership. It will apply Savana’s EHRead technology to de-identified EHRs to boost research into COVID-19 and respiratory… Read More »UK data hub to apply AI to health records for COVID-19 and respiratory research

Sorrento Collaborates with Mount Sinai to Develop Ab Combination for Neutralizing SARS-CoV-2 and other Emerging Variants of COVID-19

  • by

Shots: The companies signed an exclusive license agreement to develop COVISHIELD + two mAb cocktail against emerging variants of SARS-CoV-2 including UK (B.1.1.7), South Africa (B.1.351), and Japan/Brazil (B.1.128) variants The pre-clinical development of Ab combination (IV and intranasal) including Sorrento and Mount Sinai Abs… Read More »Sorrento Collaborates with Mount Sinai to Develop Ab Combination for Neutralizing SARS-CoV-2 and other Emerging Variants of COVID-19

ViewPoints Interview: Lumen’s Brian Finrow Shares Insight on Need for the Cheaper Methods to Engineer Antibodies as a Treatment for COVID-19

  • by

In an interview with PharmaShots, Brian Finrow, Co-Founder and CEO of Lumen Bioscience shared his views on the critical need for a scalable and cheaper method to engineer antibodies as a potential treatment for Covid-19. He also shed light on why it is time for… Read More »ViewPoints Interview: Lumen’s Brian Finrow Shares Insight on Need for the Cheaper Methods to Engineer Antibodies as a Treatment for COVID-19